Skip to main content
Erythema annulare centrifugum-type eruption in a patient undergoing cancer vaccine immunotherapy
Abstract
Sipuleucel-T is a cellular immunotherapy approved for the treatment of metastatic castration-resistant prostate cancer. We report a patient developing an immune related adverse effect from sipuleucel-T drug-induced erythema annulare centrifugum-like eruption. A brief review of the mechanism and implications of this eruption are also included.